Bio-Techne Corp. (TECH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Aug 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TECH SEC filings page.
Bio-Techne Corp. (TECH) reported $1.2B in revenue for fiscal year 2026, down 0.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is nearly flat, but restored operating margins and lower leverage make profitability more dependent on cost structure than volume growth.
The 2025 profit squeeze was not primarily a volume problem: revenue was essentially unchanged from FY2025 to FY2026, while operating margin rebounded from8.4% to20.7% . Selling, general and administrative costs fell from$589M to$452M , so the earnings swing came mainly from expense normalization rather than demand growth.
Operating cash flow was
Total liabilities fell from
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bio-Techne Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bio-Techne Corp. has an operating margin of 20.7%, meaning the company retains $21 of operating profit per $100 of revenue. This strong profitability earns a score of 76/100, reflecting efficient cost management and pricing power. This is up from 8.4% the prior year.
Bio-Techne Corp.'s revenue declined 0.4% year-over-year, from $1.2B to $1.2B. This contraction results in a growth score of 39/100.
Bio-Techne Corp. carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.55, Bio-Techne Corp. holds $4.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 90/100.
Bio-Techne Corp. converts 21.7% of revenue into free cash flow ($263.2M). This strong cash generation earns a score of 87/100.
Bio-Techne Corp.'s ROE of 8.6% shows moderate profitability relative to equity, earning a score of 61/100. This is up from 3.8% the prior year.
Bio-Techne Corp. scores 15.93, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.4B) relative to total liabilities ($478.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bio-Techne Corp. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Bio-Techne Corp. generates $1.61 in operating cash flow ($292.1M OCF vs $181.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Bio-Techne Corp. earns $26.16 in operating income for every $1 of interest expense ($251.9M vs $9.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Bio-Techne Corp. generated $321.2M in revenue in Q4 2026. This represents an increase of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.
Bio-Techne Corp.'s EBITDA was $98.4M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2926.4% from the same quarter a year earlier. Against the prior quarter it is down 1.3%.
Bio-Techne Corp. reported $54.6M in net income in Q4 2026. This represents an increase of 409.0% from the same quarter a year earlier. Against the prior quarter it is up 7.0%.
Bio-Techne Corp. earned $0.35 per diluted share (EPS) in Q4 2026. This represents an increase of 418.2% from the same quarter a year earlier. Against the prior quarter it is up 9.4%.
Cash & Balance Sheet
Bio-Techne Corp. generated $86.9M in free cash flow in Q4 2026, representing cash available after capex. This represents a decrease of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 12.1%.
Bio-Techne Corp. held $264.7M in cash against $200.0M in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Margins & Returns
Bio-Techne Corp.'s gross margin was 65.8% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Bio-Techne Corp.'s operating margin was 23.1% in Q4 2026, reflecting core business profitability. This is up 30.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Bio-Techne Corp.'s net profit margin was 17.0% in Q4 2026, showing the share of revenue converted to profit. This is up 22.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Bio-Techne Corp.'s ROE was 2.6% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Capital Allocation
Bio-Techne Corp. invested $23.9M in research and development in Q4 2026. This represents a decrease of 8.0% from the same quarter a year earlier. Against the prior quarter it is up 2.1%.
Bio-Techne Corp. spent $41.7M on share buybacks in Q4 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 58.4% from the same quarter a year earlier.
Bio-Techne Corp. invested $8.5M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 73.4% from the same quarter a year earlier. Against the prior quarter it is down 6.7%.
TECH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $321.2M+1.3% | $311.4M-1.5% | $295.9M-0.4% | $286.6M-1.0% | $317.0M+3.5% | $316.2M+4.2% | $297.0M+9.0% | $289.5M+4.5% |
| Cost of Revenue | $109.8M-7.1% | $103.1M+1.5% | $104.6M+1.4% | $98.4M-7.5% | $118.2M+15.0% | $101.6M+2.8% | $103.1M+7.4% | $106.4M+16.0% |
| Gross Profit | $211.4M+6.3% | $208.3M-2.9% | $191.3M-1.3% | $188.1M+2.8% | $198.8M-2.2% | $214.6M+4.9% | $193.9M+9.8% | $183.0M-1.2% |
| R&D Expenses | $23.9M-8.0% | $23.5M-4.6% | $23.1M-7.6% | $24.2M+1.6% | $26.0M+8.5% | $24.6M-4.6% | $25.0M+9.2% | $23.9M-0.5% |
| SG&A Expenses | $113.2M-42.4% | $109.3M-27.7% | $113.7M-6.4% | $116.2M-2.5% | $196.6M+47.3% | $151.3M+35.3% | $121.5M+5.0% | $119.2M+13.1% |
| Operating Income | $74.3M+411.3% | $75.5M+95.0% | $54.5M+14.9% | $47.7M+19.2% | -$23.9M-152.1% | $38.7M-42.2% | $47.4M+24.8% | $40.0M-28.4% |
| EBITDA | $98.4M+2926.4% | $99.7M+50.4% | $79.2M+6.3% | $72.0M+5.7% | $3.3M-95.6% | $66.3M-29.7% | $74.5M+13.2% | $68.1M-19.3% |
| Interest Expense | $2.1M-2.5% | $2.4M+19.7% | $2.2M+1.1% | $2.9M+34.8% | $2.2M-13.2% | $2.0M-49.9% | $2.1M-50.4% | $2.2M-55.5% |
| Income Tax | $16.1M+410.0% | $20.2M+28.6% | $12.8M+60.0% | $9.8M+49.2% | -$5.2M-583.2% | $15.7M+30.4% | $8.0M+34.9% | $6.6M+557.9% |
| Net Income | $54.6M+409.0% | $51.0M+126.0% | $38.0M+8.9% | $38.2M+13.6% | -$17.7M-143.6% | $22.6M-54.0% | $34.9M+27.0% | $33.6M-34.1% |
| EPS (Basic) | $0.35+418.2% | $0.33+135.7% | $0.24+9.1% | $0.25+19.0% | -$0.11-142.3% | $0.14-54.8% | $0.22+29.4% | $0.21-34.4% |
| EPS (Diluted) | $0.35+418.2% | $0.32+128.6% | $0.24+9.1% | $0.24+14.3% | -$0.11-142.3% | $0.14-54.8% | $0.22+29.4% | $0.21-32.3% |
| Diluted Shares (Avg) | N/A | 157M-1.0% | 157M-2.3% | 156M-3.0% | N/A | 159M-1.0% | 161M+0.4% | 161M-0.5% |
TECH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6B+1.1% | $2.6B-3.5% | $2.5B-5.5% | $2.5B-7.7% | $2.6B-5.4% | $2.6B-2.8% | $2.7B-2.2% | $2.7B-0.7% |
| Current Assets | $744.4M+22.4% | $688.0M+9.7% | $637.4M+0.4% | $609.5M-6.0% | $608.3M-1.5% | $627.2M+2.7% | $634.6M+7.4% | $648.6M+9.7% |
| Cash & Equivalents | $264.7M+63.2% | $209.8M+49.2% | $172.9M-2.6% | $145.0M-22.7% | $162.2M+6.8% | $140.7M+0.5% | $177.5M+36.4% | $187.5M+26.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0 |
| Inventory | $195.7M+3.3% | $201.2M+5.3% | $205.4M+9.1% | $203.2M+9.8% | $189.4M+5.4% | $191.1M+6.5% | $188.4M+4.2% | $185.0M-0.6% |
| Accounts Receivable | $216.6M+4.7% | $214.6M-9.5% | $184.6M-15.3% | $183.9M-17.8% | $206.9M-14.3% | $237.1M+4.1% | $217.9M+5.1% | $223.7M+9.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $975.4M-0.6% | $977.8M+0.9% | $980.6M+1.7% | $978.9M-0.4% | $980.9M+0.9% | $968.6M-0.2% | $964.6M-1.6% | $982.6M+1.4% |
| Total Liabilities | $478.5M-25.1% | $465.3M-25.7% | $511.7M-13.6% | $560.3M-6.2% | $639.1M+0.6% | $626.2M-11.4% | $591.9M-22.8% | $597.4M-21.2% |
| Current Liabilities | $163.7M-6.9% | $153.3M-9.4% | $140.4M-12.9% | $144.5M+1.7% | $175.8M+10.3% | $169.2M+12.9% | $161.3M+19.2% | $142.1M+11.3% |
| Non-Current Liabilities | $314.8M-32.0% | $312.0M-31.7% | $371.3M-13.8% | $415.8M-8.7% | $463.2M-2.6% | $457.0M-17.9% | $430.7M-31.9% | $455.2M-27.7% |
| Long-Term Debt | $200.0M-42.2% | $200.0M-39.4% | $260.0M-13.3% | $300.0M0.0% | $346.0M+8.5% | $330.0M-15.2% | $300.0M-32.9% | $300.0M-31.8% |
| Total Equity | $2.1B+9.9% | $2.1B+3.3% | $2.0B-3.2% | $2.0B-8.1% | $1.9B-7.3% | $2.0B+0.2% | $2.1B+5.9% | $2.1B+7.1% |
| Retained Earnings | $1.1B+7.3% | $1.1B-4.3% | $1.1B-14.0% | $1.1B-19.3% | $1.1B-19.6% | $1.2B-7.8% | $1.3B+2.0% | $1.3B+1.0% |
TECH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $95.4M-2.8% | $86.7M+110.8% | $82.4M-2.3% | $27.6M-56.8% | $98.2M+30.1% | $41.1M-49.2% | $84.3M+1.5% | $63.9M+7.6% |
| Depreciation & Amortization | $24.1M-11.0% | $24.2M-12.3% | $24.7M-8.8% | $24.3M-13.5% | $27.1M-3.4% | $27.6M+1.0% | $27.1M-2.6% | $28.1M-1.4% |
| Stock-Based Compensation | N/A | N/A | N/A | $11.7M+14.7% | N/A | N/A | N/A | $10.2M+0.9% |
| Capital Expenditures | $8.5M+73.4% | $9.1M-10.2% | $5.9M-13.2% | $5.4M-41.5% | $4.9M-72.8% | $10.1M-38.4% | $6.8M-54.1% | $9.2M-32.5% |
| Free Cash Flow | $86.9M-6.8% | $77.6M+150.3% | $76.5M-1.3% | $22.2M-59.4% | $93.3M+62.2% | $31.0M-52.0% | $77.5M+13.6% | $54.7M+19.5% |
| Investing Cash Flow | -$7.1M-1838.2% | -$5.8M+34.4% | -$5.9M-17.7% | $605K+102.8% | $406K+104.6% | -$8.9M+46.0% | -$5.0M+78.7% | -$21.7M+85.9% |
| Financing Cash Flow | -$33.2M+63.3% | -$42.7M+37.2% | -$49.0M+41.6% | -$44.2M-282.0% | -$90.5M-50.5% | -$68.0M-29.8% | -$83.8M-3.0% | -$11.6M-116.2% |
| Dividends Paid | $12.5M+0.8% | $12.5M-0.5% | $12.5M-2.1% | $12.4M-1.9% | $12.4M-1.9% | $12.6M0.0% | $12.7M+1.4% | $12.7M+0.3% |
| Share Buybacks | $41.7M-58.4% | $0-100.0% | $0 | $24K | $100.1M | $100.0M | N/A | N/A |
TECH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.8%+3.1pp | 66.9%-1.0pp | 64.6%-0.6pp | 65.6%+2.4pp | 62.7%-3.7pp | 67.9%+0.4pp | 65.3%+0.5pp | 63.2%-3.6pp |
| Operating Margin | 23.1%+30.7pp | 24.2%+12.0pp | 18.4%+2.5pp | 16.6%+2.8pp | -7.5%-22.5pp | 12.2%-9.8pp | 16.0%+2.0pp | 13.8%-6.4pp |
| Net Margin | 17.0%+22.6pp | 16.4%+9.2pp | 12.8%+1.1pp | 13.3%+1.7pp | -5.6%-18.8pp | 7.1%-9.0pp | 11.8%+1.7pp | 11.6%-6.8pp |
| Return on Equity | 2.6%+3.5pp | 2.5%+1.3pp | 1.9%+0.2pp | 1.9%+0.4pp | -0.9%-2.9pp | 1.1%-1.3pp | 1.7%+0.3pp | 1.6%-1.0pp |
| Return on Assets | 2.1%+2.8pp | 2.0%+1.1pp | 1.5%+0.2pp | 1.5%+0.3pp | -0.7%-2.2pp | 0.9%-0.9pp | 1.3%+0.3pp | 1.2%-0.6pp |
| Current Ratio | 4.55+1.1x | 4.49+0.8x | 4.54+0.6x | 4.22-0.3x | 3.46-0.4x | 3.71-0.4x | 3.94-0.4x | 4.56-0.1x |
| Debt-to-Equity | 0.09-0.1x | 0.10-0.1x | 0.130.0x | 0.150.0x | 0.180.0x | 0.160.0x | 0.14-0.1x | 0.14-0.1x |
| Asset Turnover | 0.120.0x | 0.120.0x | 0.120.0x | 0.110.0x | 0.120.0x | 0.120.0x | 0.110.0x | 0.110.0x |
| FCF Margin | 27.1%-2.4pp | 24.9%+15.1pp | 25.9%-0.3pp | 7.8%-11.2pp | 29.4%+10.6pp | 9.8%-11.5pp | 26.1%+1.1pp | 18.9%+2.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bio-Techne Corp. TECH | FY2026 | $1.2B | $181.9M | 15.0% | $11.4B | 74/100 |
| Jazz Pharmaceuticals, Inc. JAZZ | FY2025 | $4.3B | -$356.1M | -8.3% | $14.4B | 53/100 |
| Halozyme Therapeutics, Inc. HALO | FY2025 | $1.4B | $316.9M | 22.7% | $12.5B | 78/100 |
| Verona Pharma plc VRNA | FY2024 | $42.3M | -$173.4M | N/A | $9.2B | 60/100 |
| Revolution Medicines, Inc. RVMD | FY2025 | $0 | -$1.1B | N/A | $40.3B | — |
Where Bio-Techne Corp. Ranks
Frequently Asked Questions
What is Bio-Techne Corp.'s annual revenue?
Bio-Techne Corp. (TECH) reported $1.2B in total revenue for fiscal year 2026. This represents a -0.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio-Techne Corp.'s revenue growing?
Bio-Techne Corp. (TECH) revenue declined by 0.4% year-over-year, from $1.2B to $1.2B in fiscal year 2026.
Is Bio-Techne Corp. profitable?
Yes, Bio-Techne Corp. (TECH) reported a net income of $181.9M in fiscal year 2026, with a net profit margin of 15.0%.
What is Bio-Techne Corp.'s EBITDA?
Bio-Techne Corp. (TECH) had EBITDA of $349.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bio-Techne Corp. have?
As of fiscal year 2026, Bio-Techne Corp. (TECH) had $264.7M in cash and equivalents against $200.0M in long-term debt.
What is Bio-Techne Corp.'s gross margin?
Bio-Techne Corp. (TECH) had a gross margin of 65.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bio-Techne Corp.'s operating margin?
Bio-Techne Corp. (TECH) had an operating margin of 20.7% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Bio-Techne Corp.'s net profit margin?
Bio-Techne Corp. (TECH) had a net profit margin of 15.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Does Bio-Techne Corp. pay dividends?
Yes, Bio-Techne Corp. (TECH) paid $0.32 per share in dividends during fiscal year 2026.
What is Bio-Techne Corp.'s return on equity (ROE)?
Bio-Techne Corp. (TECH) has a return on equity of 8.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Bio-Techne Corp.'s free cash flow?
Bio-Techne Corp. (TECH) generated $263.2M in free cash flow during fiscal year 2026. This represents a 2.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bio-Techne Corp.'s operating cash flow?
Bio-Techne Corp. (TECH) generated $292.1M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Bio-Techne Corp.'s total assets?
Bio-Techne Corp. (TECH) had $2.6B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Bio-Techne Corp.'s capital expenditures?
Bio-Techne Corp. (TECH) invested $28.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Bio-Techne Corp. spend on research and development?
Bio-Techne Corp. (TECH) invested $94.8M in research and development during fiscal year 2026.
What is Bio-Techne Corp.'s current ratio?
Bio-Techne Corp. (TECH) had a current ratio of 4.55 as of fiscal year 2026, which is generally considered healthy.
What is Bio-Techne Corp.'s debt-to-equity ratio?
Bio-Techne Corp. (TECH) had a debt-to-equity ratio of 0.09 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio-Techne Corp.'s return on assets (ROA)?
Bio-Techne Corp. (TECH) had a return on assets of 7.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Bio-Techne Corp.'s P/E ratio?
Bio-Techne Corp. (TECH) trades at 62.5x earnings, its market capitalization divided by net income of $181.9M net income, FY2026. The market capitalization is $11.4B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bio-Techne Corp.'s price-to-sales ratio?
Bio-Techne Corp. (TECH) trades at 9.4x sales, its market capitalization divided by revenue of $1.2B revenue, FY2026. The market capitalization is $11.4B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bio-Techne Corp.'s Altman Z-Score?
Bio-Techne Corp. (TECH) has an Altman Z-Score of 15.93, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio-Techne Corp.'s Piotroski F-Score?
Bio-Techne Corp. (TECH) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio-Techne Corp.'s earnings high quality?
Bio-Techne Corp. (TECH) has an earnings quality ratio of 1.61x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bio-Techne Corp. cover its interest payments?
Bio-Techne Corp. (TECH) has an interest coverage ratio of 26.16x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bio-Techne Corp.?
Bio-Techne Corp. (TECH) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.